CoChat

BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis

King, Talmadge E., Brown, Kevin K., Raghu, Ganesh, du Bois, Roland M., Lynch, David A., Martinez, Fernando, Valeyre, Dominique, Leconte, Isabelle, Morganti, Adele, Roux, Sébastien, Behr, Juergen · 2011 · American Journal of Respiratory and Critical Care Medicine

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Rationale: A previous trial of bosentan in idiopathic pulmonary fibrosis (IPF) showed a trend to delayed IPF worsening or death. Also, improvements in some measures of dyspnea and health-related quality of life were observed. Objectives: To demonstrate that bosentan delays IPF worsening or death. Methods: Prospective, randomized (2:1), double-blind, placebo-controlled, event-driven, parallel-group, morbidity–mortality trial of bosentan in adults with IPF of less than 3 years’ duration, confirmed by surgical lung biopsy, and without extensive honeycombing on high-resolution computed tomography. The primary endpoint was time to IPF worsening (a confirmed decrease from baseline in FVC ≥ 10% and diffusing capacity of the lung for carbon monoxide ≥ 15%, or acute exacerbation of IPF) or death up to End of Study. Effects of bosentan on health-related quality of life, dyspnea, and the safety and tolerability of bosentan were investigated. Measurements and Main Results: Six hundred sixteen patients were randomized to bosentan (n = 407) or placebo (n = 209). No significant difference between treatment groups was observed in the primary endpoint analysis (hazard ratio, 0.85; 95% confidence interval, 0.66–1.10; P = 0.2110). No treatment effects were observed on health-related quality of life or dyspnea. Some effects of bosentan treatment were observed in changes from baseline to 1 year in FVC and diffusing capacity of the lung for carbon monoxide. The safety profile for bosentan was similar to that observed in other trials. Conclusions: The primary objective in the Bosentan Use in Interstitial Lung Disease-3 trial was not met. Bosentan was well tolerated. Clinical trial registered with www.clinicaltrials.gov (NCT 00391443).

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.201011-1874oc

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Research works printed but not linked: 2

  1. King, 2010, The BUILD-3 trial: a prospective, randomized, double-blind, placebo-controlled study of bosentan in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 181, A6838
  2. du Bois, 2010, Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis (IPF) [abstract], Am J Respir Crit Care Med, 181, A2499

Cited by

See all 719

Metadata

Authors
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., & Behr, J.
Affiliations
  • University of California, San Francisco (US)
  • Department of Medicine
  • University of Washington (US)
  • Imperial College, London, United Kingdom
  • National Jewish Health (US)
  • Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan
  • Université Paris Cité (FR)
  • Actelion (Switzerland) (CH)
  • Ruhr University Bochum (DE)
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2011-07-01
Volume
184
Issue
1
Pages
92-99
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2145491879
Cited by
718
References
54
Citations by year
2026: 11 · 2025: 19 · 2024: 20 · 2023: 24 · 2022: 33 · 2021: 30 · 2020: 23 · 2019: 25 · 2018: 39 · 2017: 53 · 2016: 48 · 2015: 57 · 2014: 54 · 2013: 65 · 2012: 56
FWCI
62.08
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
bosentan, idiopathic pulmonary fibrosis, endothelin receptor antagonists, disease progression, mortality, forced vital capacity, diffusing capacity for carbon monoxide, health-related quality of life, dyspnea, drug safety and tolerability, interstitial lung disease
MeSH terms
Bosentan, Adolescent, Adult, Aged, Antihypertensive Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Pulmonary Diffusing Capacity, Quality of Life, Sulfonamides, Vital Capacity, Survival Rate, Disease Progression, Endpoint Determination, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201011-1874oc
The paper
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., & Behr, J. (2011). BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201011-1874oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.